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ADP-Specific Sensors Enable Universal Assay
of Protein Kinase Activity
which preferentially phosphorylate a serine and/or thre-
onine residue. More recently, a third class of protein
kinases has been described that phosphorylates the
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transduction activities of protein kinases are critical for
normal functioning of the eukaryotic cell and for its re-
sponses to a wide variety of extracellular or environmen-Summary
tal stimuli. Aberrant activity of protein kinases is impli-
cated in numerous diseases, ranging from cancer toTwo molecular sensors that specifically recognize
inflammation and immune disorders [3–8]. Thus, proteinADP in a background of over 100-fold molar excess
kinases represent important targets for discovery of newof ATP are described. These sensors are nucleic-acid
pharmaceutical agents.based and comprise a general method for monitoring
Despite the facts that protein kinases represent anprotein kinase activity. The ADP-aptamer scintillation
enormous reservoir of targets for small molecule antag-proximity assay is configured in a single-step, homo-
onists and that the number of small molecules able togeneous format while the allosteric ribozyme (Ribo-
inhibit kinases is also relatively large, there are currentlyReporter) sensor generates a fluorescent signal upon
only two FDA-approved small molecule drugs that targetADP-dependent ribozyme self-cleavage. Both sys-
protein kinases [4, 9]. These are Gleevec (Novartis) [10,tems perform well when configured for high-throughput
11], which targets the three kinases Brc-Abl, c-Kit andscreening and have been used to rediscover a known
PDGFR, and Iressa (AstraZeneca) [12, 13], which targetsprotein kinase inhibitor in a high-throughput screening
EGFR (HER1) . Since diverse kinases share a commonformat.
mechanism, specificity among them is very difficult to
achieve with small molecule inhibitors. Thus, while many
Introduction ATP analogs and related compounds that bind to the
active site may function as excellent kinase inhibitors,
Enzymes represent one of the largest classes of protein most suffer from toxicities associated with poor target
targets for pharmaceutical development. High throughput specificity [5]. Since the probability of finding a small
screening (HTS) of compound libraries to identify mole- molecule inhibitor with the appropriate activity and
cules that inhibit the catalytic activity of specific kinases, specificity is low, the discovery effort greatly benefits
helicases, proteases, and other enzymes is a major fo- from the development of efficient screening methods
cus of pharmaceutical industry efforts. Strategies for that maximize the number of evaluated candidates.
the detection of enzyme activity in HTS formats that can Currently, screens for kinase inhibitors are estimated
readily translate to multiple targets have the potential to represent 10%–20% of the HTS effort in the pharma-
to greatly accelerate therapeutic discovery. Agents such ceutical industry, and several assay formats have been
as aptamers that very selectively recognize the common developed to support these large-scale undertakings
product of an enzyme reaction class but not the corre- [14–16]. Most biochemical assays to detect protein ki-
sponding substrate(s) could effectively enable such nase activity monitor phosphorylation of the protein
strategies to the extent that enzyme product recognition substrate or of a specially engineered peptide surrogate.
can be readily transduced into a detectible signal. Ex- Traditional enzyme-linked immunosorbent assay (ELISA)
ploiting the ability to select in vitro for and against recog- formats require custom anti-phosphopeptide-specific
nition of product (ADP) and substrate (ATP), respec- antibodies and involve multiple reagent additions and
tively, we isolated an aptamer that effectively monitors plate washing steps that compromise throughput [17].
the catalytic activity of protein kinases. We show that More recently, fluorescence polarization [18, 19] and
the aptamer and a catalytically active ribozyme (RiboRe- time-resolved fluorescence resonance energy transfer
porter) derived from the aptamer can be configured to (TR-FRET) [20–24] assays have been developed for pro-
generate radiometric and fluorescent readouts, respec- tein kinase screens. Nevertheless, like ELISAs, these
tively, in HTS formats. formats often rely on availability of anti-phosphopep-
Protein kinases comprise a large family of enzymes tide-specific antibodies. Several scintillation proximity
that catalyze the transfer of a phosphate group from assay (SPA) formats for HTS of protein kinases have also
a nucleoside triphosphate (usually ATP) to a protein been reported that use common immobilization formats
substrate, yielding a phosphorylated protein and a nu- (e.g., biotin/streptavidin) to capture radiolabeled pep-
cleoside diphosphate (ADP). The majority of protein ki- tide reaction products on scintillant-containing surfaces
nases fall into either of two classes: those which prefer- [20, 22, 25, 26]. Generally, however, the peptide sub-
entially phosphorylate a tyrosine residue and those strate used in such assay formats must be optimized
for each particular kinase and engineered extensively
for purposes of detection.*Correspondence: diener@archemix.com
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Figure 1. Selection and Initial Characterization of an ADP-Specific Aptamer
(A) Schematic representation of the selection scheme used to generate ADP specific aptamers.
(B) Titration of 3H-ADP against clone F11 from the aptamer selection immobilized in a neutravidin coated scintillation proximity assay (SPA)
flash plate via hybridization with a biotinylated capture oligo. Signal over background was calculated by dividing signal with the immobilized
best aptamer clone by the signal for immobilized naive pool RNA at the same concentration of 3H-ADP.
(C) Proposed secondary structure of the clone F11 from the original aptamer selection with results from sequence analysis of the doped
reselection mapped onto it in color. Red indicates positions that were not conserved, green indicates positions that were moderately conserved,
blue indicates positions that were highly conserved, black indicates positions that were held constant during reselection, stars indicate
positions where covariation was observed, and arrows indicate the primer boundaries from the original selection.
(D) Sequence and secondary structure of the aptamer sensor used in competition and protein kinase assays. The sequence was designed
based upon the results of the reselection, with stabilizing helices flanking the asymmetric bulge region. The sequence was designed with an
extended 3 sequence for use in an oligo capture format in addition to capture by direct 3-biotinylation.
(E) Competition experiments using the optimized aptamer shown in (D), directly biotinylated at the 3 end and captured in a neutravidin coated
96-well SPA plate. 1 M 3H-ADP was added in selection buffer and then competed off with increasing concentrations of unlabeled ADP, ATP,
AMP, and cAMP.
Our approach to the establishment of novel protein of ADP to the depletion of the chromophore NADH
through the activities of pyruvate kinase and lactatekinase assay formats relies on detection of ADP rather
than the phosphopeptide product of enzymatic activity. dehydrogenase [27]. While this assay can be configured
for HTS, because of its colorimetric readout it typicallyThe classical detection system couples the generation
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Table 2. Reported KmATP Values for Several Protein KinasesTable 1. Relative Affinities of Various Ligands Binding to the
ADP Aptamer as Estimated from the IC50 in a Competition Kinase KmATP (M) ReferenceExperiment with 3H-ADP and Unlabeled Competitor in the SPA
Format ERK 140 [44, 45, 50]
MEK1-ED 6 [54]Competitor IC50 (M) IC50 Comp./IC50 ADP p38 23 [53]
MAPKAPK2 43 [55]ADP 3 1
ATP 1000 300 Rho-kinase II 21 [56, 57]
Cdk2/5 3 [58]AMP 7000 2300
cAMP 10000 3300 P50/CSK 195 [59–64]
IRK 40 [64, 65]GDP 2000 700
GTP 4000 1300 pp60src 80 [67–72]
PKA 7 [62]GMP 6000 2000
cGMP 13000 4300 IKK/ 0.13 [77]
Staurosporinea 2000 700
Iodotubercidina 1000 300
a For these compounds, solubility became an issue at concentrations In order to better characterize clone F11 from the
greater than 2 and 1 mM, respectively.
initial selection, a doped reselection was undertaken
using a partially randomized version of the best binding
clone sequence as described in Experimental Proce-
dures. After three rounds of reselection, the pool washas more limited sensitivity. Furthermore, assays that
again cloned and sequenced. Based on both conserva-use a secondary enzymatic readout require extensive
tion and covariation within the sequence set, we werecounter screens (e.g., to control for pyruvate kinase and
able to determine the secondary structure of the ADPlactate dehydrogenase-inhibiting compounds, in this
aptamer and thus design functional minimized con-particular case). Here, we describe the development of
structs for use in assay development (Figures 1C andtwo highly selective RNA-based sensors that can be
1D). Using the SPA competition assay and directly bio-used to monitor ADP formation in the presence of excess
tinylated minimized aptamer, we estimate the affinity ofATP. The first sensor is an ADP-specific aptamer, and
the ADP aptamer for ADP to be approximately 3 M.the second is an allosteric hammerhead ribozyme (also
Remarkably, the aptamer discriminates over 300-foldtermed RiboReporter sensor) Both aptamers and Ribo-
against ATP and other nucleotide derivatives (Figure 1EReporter sensors are structurally distinctive nucleic
and Table 1). Specifically, the IC50 values for competitionacids evolved through in vitro selection to bind their
of the common kinase inhibitors staurosporine and iodo-targets with high affinity and specificity [28–39]. Taken
tubercidin (ITU) with ADP for sensor binding are in thetogether, aptamer and RiboReporter ADP sensor mole-
low millimolar range (Table 1). Since concentrations ofcules form the basis of efficient and broadly generaliz-
test compounds typically used in HTS assays are in the
able assay formats for protein kinase activity.
low- to mid-micromolar range, the level of ADP specific-
ity provided by this sensor will translate into minimal
requirements for rescreening caused by test com-
Results and Discussion
pounds directly competing with ADP for sensor binding.
It is worth noting that the degree of discrimination
ADP Aptamer Selection
between ADP and ATP is dependent on the purity of
Specific recognition of ADP in the presence of excess the ATP used. Solutions of purified ATP typically contain
ATP is conceptually challenging as the two molecules up to 1% ADP. As such, the experimentally observed
differ by only a single phosphate group. An extensively discrimination may represent a lower limit relative to the
studied aptamer to ATP, reported almost a decade ago actual ADP/ATP discrimination of the aptamer. Since KM
[40], does not discriminate between ATP, ADP, and values for ATP binding for many protein kinases are in
AMP. In order to build ADP/ATP discrimination into our the high-nanomolar to mid-micromolar range (Table 2),
aptamer, we employed a series of negative selection kinase assays are typically run at mid-nanomolar to low-
steps during the SELEX [41–43] process (Figure 1A and micromolar ATP concentrations. In these ranges, given
Experimental Procedures) in which RNAs that bound to an aptamer binding affinity of 3 M, 99% pure ATP
both ATP and ADP were removed from the pool popula- will provide 100-fold discrimination and should be more
tion. After 16 rounds of selection, the aptamer pool was than sufficient to detect ADP produced by kinase activity
cloned and sequenced, and individual aptamer clones over background signal.
were immobilized via oligonucleotide capture in 96-well
neutravidin coated scintillation proximity assay plates. ADP Aptamer-Based Sensor
Individual clones were screened on the basis of their The ADP-selective aptamer was configured for use in a
ability to both bind to 3H-ADP and to discriminate be- scintillation proximity assay (ADP-SPA) that can detect
tween ADP and ATP by competition with unlabeled com- protein kinase activity in a high-throughput setting (Fig-
petitor ADP or ATP. As shown (Figure 1B), the best ure 2A). In this scheme, the minimized ADP aptamer
clone, F11, has a lower limit of 3H-ADP detection in (Figure 1D) was immobilized via oligonucleotide capture
the scintillation proximity assay format in the range of on a neutravidin-coated 96-well plate embedded with
50–100 nM (see Experimental Procedures for details on scintillant. When 3H-ATP is used as the substrate in a
protein kinase reaction, the 3H-ADP product is capturedthe SPA assay).
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Figure 2. The ADP Aptamer-Based Scintillation Proximity Assay
(A) Schematic representation of the ADP-SPA assay configuration. Optimized aptamer either directly 3-biotinylated or hybridized via the 3-
sequence tag to a 5-biotinylated DNA capture oligo is immobilized onto a neutravidin coated scintillation plate. 3H-ATP is used as the substrate
for the kinase reaction, yielding 3H-ADP, which is captured by the aptamer on the plate surface, generating a signal.
(B) ADP aptamer-based SPA measuring the activity of the protein kinase pERK2 (15 nM) using MBP (50 M) and 3H-ATP (2.7 M) as substrates.
Reactions were done in the absence (blue diamonds) or presence (magenta squares) of 1 M of the kinase inhibitor staurosporine.
(C) Inhibition of protein kinase activity by staurosporine or iodotubercidin in the ADP aptamer SPA. Effect of protein kinase inhibitors was
assayed in the presence of 30 nM pERK2, 1.4 M 3H-ATP, and 10 M MBP. Activity of pERK2 at various inhibitor concentrations was estimated
from initial rates of reaction. Rates in the presence of inhibitor were normalized to the rate of reaction in the absence of any inhibitor. The
IC50 values determined for both staurosporine and iodotubercidin using the ADP aptamer SPA were 1 M. The reported IC50 values are 1 M
and 0.9 M for staurosporine and iodotubercidin inhibition of pERK2, respectively [48].
by the aptamer on the plate surface, generating a signal radioactivity. Second, we were interested in determining
whether such a sensor configured in an enzymatic for-(Figure 2A). All of the assay components can be added
mat might have greater sensitivity than the aptamer sen-in a single step, and the output can be analyzed either
sor used in the ADP-SPA format.kinetically or as a single point determination. Figure 2B
Briefly, the ADP aptamer was appended to a hammer-compares the time course of the production of ADP
head ribozyme core [48, 49] in two different relativefor protein kinase pERK2-catalyzed phosphorylation of
orientations via a connecting stem consisting of eightmyelin basic protein (MBP) [44–46] in the presence and
randomized nucleotides to generate two pools of po-absence of 1M staurosporine. As can be seen, the SPA
tential allosteric ribozyme molecules (Figures 3A andassay provides a direct kinetic profile of the biochemical
3B). The two pools were used because it was not clearreaction. Most significantly, IC50 values determined for
a priori which orientation would yield superior ribo-protein kinase inhibitors staurosporine and iodotuber-
zymes. These pools of molecules were subjected tocidin acting against pERK2 using the ADP aptamer scin-
successive rounds of selection in which molecules thattillation proximity assay were in good agreement with
were catalytically active in the absence of ADP weretheir reported values (Figure 2C) [47].
selected against, and those that were active in the pres-
ence of ADP were amplified and carried forward. After
Selection of an ADP-Specific several rounds of selection, the pools were greatly en-
RiboReporter Sensor riched for RNA molecules whose catalytic activity was
In addition to the aptamer-based SPA assay, the mini- activated by ADP (Figure 3C). Pools were cloned, se-
mized ADP aptamer was used to construct a RiboRe- quenced, and screened on the basis of their ADP-
porter sensor that detects ADP in a background of ATP dependent reactivity and selectivity against ATP. The
concomitant with generation of a fluorescent signal. sequence and proposed secondary structure of the best
Generation of a RiboReporter sensor was undertaken clone from the selection is shown (Figure 4A). It is worth
for two reasons. First, we were interested in generating noting that the sequence of the best connecting stem
was not that of a previously reported communicationa detection system that functioned without the use of
ADP-Specific Sensors
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nally, a fluorescence-based signaling system was de-
vised by appending fluorescein to the 3 terminus of the
allosteric ribozyme and hybridizing an oligonucleotide
labeled at its 5 end with Dabcyl immediately proximal to
this terminus (Figure 4B and Experimental Procedures).
The proximity of the Dabcyl group to the fluorescein
quenches fluorescence. Upon binding to ADP, the sen-
sor undergoes self-cleavage at a site near the 3end,
releasing the fluorescently labeled product and generat-
ing a fluorescent signal at 535 nanometers.
The ADP RiboReporter sensor is used in a two-step
process. In the first step, the protein kinase reaction is
run in buffer with the appropriate substrate and ATP in
the presence or absence of potential small molecule
inhibitors. The protein kinase activity is then quenched,
at a specific time such that it is still in the linear region
of its reaction profile, by addition of 1 volume of 600 nM
RiboReporter in buffer additionally containing 0.1% SDS
(see Experimental Procedures). Addition of SDS inhibits
protein enzyme activity but not ribozyme activity. The
concentration of ADP produced by the kinase reaction
is then measured in the second step in a kinetic format in
which the rate of production of oligonucleotide cleavage
product versus ADP concentration is measured. The
rate constant of the self-cleavage reaction increases
linearly with ADP concentration, with a lower limit of
detection of 1–5 M ADP (Figure 5A).
The ADP RiboReporter sensor was used to detect
pERK2 protein kinase activity in a 96-well format using
the synthetic peptide, ERKtide (ATGPLSPGPFGRR) [50],
as a substrate. In a pilot screen, 77 test drug-like com-
pounds identified from a chemical library based on Lip-
inski’s “rule of 5” [51] and three positive control wellsFigure 3. Selection of an ADP-Specific RiboReporter
containing staurosporine were each tested at a final(A) Proposed secondary structure of ADP RiboReporter sensor
concentration of 10 M. As shown (Figure 5B), thepool A.
(B) Proposed secondary structure of riboreporter sensor pool B. ADP RiboReporter sensor unambiguously identified mi-
(C) Ratio of riboreporter sensor cleavage in the presence of ADP croplate wells containing the staurosporine inhibitor,
over the cleavage in the absence of ADP during the course of the and its overall performance was acceptable for an unop-
selections. timized assay (Z-factor [52]  0.23). Furthermore, using
the ADP RiboReporter in this format, 5–10 moles of
sensor would be enough to screen a 100,000 compoundmodule and furthermore that that particular module did
library.not yield allosteric hammerhead ribozymes with the ADP
aptamer in either orientation (data not shown) [35]. Fi- The ADP aptamer scintillation proximity assay and the
Figure 4. Optimization of the Best ADP-Spe-
cific RiboReporter for Fluorescence-Based
Detection
(A) Proposed secondary structure of the best
ADP-dependent RiboReporter sensor from
the two selections. (B) ADP RiboReporter
sensor format. The sensor shown in (A) was
configured into a fluorescence-based for-
mat. Upon binding of ADP, the ribozyme un-
dergoes self-cleavage and releases a short
fluorescein-labeled product oligonucleotide,
which generates a fluorescent signal at 535
nm upon excitation at 488 nm.
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the affinity of the sensor for the target ligand and the
detection scheme [76]. Thus, further selection or doped
reselection would be necessary to improve the sensitiv-
ity of the current RiboReporter sensor.
Ultimately, these detection limits define subsets of
protein kinases that may be assayed using this genera-
tion of sensors. The ADP aptamer scintillation proximity
assay is appropriate for protein kinases with KmATP values
in the low-micromolar range, while the ADP RiboRe-
porter sensor is suitable for protein kinases with KmATP
values in the mid-micromolar range. These reported
KmATP values [45, 46, 50, 53–75, 77], taken together,
cover a substantial range of the spectrum of kinases
(Table 2). Continued selection and optimization of an
ADP aptamer and/or RiboReporter sensor with an ap-
proximate 10-fold increase in affinity for ADP is ex-
pected to enable activity assays for nearly every known
protein kinase using a single biochemical format. Fur-
thermore, while the detection limit of the RiboReporter
sensor is higher than that of the original ADP-SPA, the
RiboReporter sensor still retains the specificity of the
aptamer and is functional in a nonradioactive format.
Significance
As currently configured, each of our assay formats
has certain strengths relative to the other. The aptamer
SPA assay offers the advantage of a single-step reac-Figure 5. Detection of ADP by the RiboReporter in a High-
tion that can be monitored in real time, providing aThroughput Screening Format
direct kinetic measurement of each individual reaction(A) The fluorescent signal of the ADP RiboReporter sensor is linearly
in the screen. While the RiboReporter sensor requiresdependent upon ADP concentration. The RiboReporter sensor (240
nM ribozyme, 1.2 M quencher oligonucleotide) was incubated with a two-step process, it offers the advantage of a nonra-
various concentrations of ADP in 50 mM HEPES (pH 8.0), 100 mM dioactive, fluorescence-based readout. However, in
NaCl, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM DTT in a 96-well plate, both cases, the exquisite selectivity demonstrated by
and the rate of generation of signal was measured using a Fusion the sensors against ATP, ATP analogs, and nucleo-fluorescence detector. The initial reaction rates are plotted versus
tides in general suggests that candidate drug com-[ADP]. The inset shows the raw fluorescence emission signal at 535
pounds and other components of kinase reactionsnanometers versus time.
(B) ADP RiboReporter sensor performance in a pilot HTS. 25 nM used in HTS are unlikely to interfere with the detection
activated ERK was incubated with 100M ATP and 100M ERKtide of ADP. Therefore, unlike traditional enzymatic for-
in 50 mM HEPES (pH 8.0), 100 mM NaCl, 10 mM MgCl2, 0.1 mg/ml mats for ADP detection, minimal rescreening of poten-
BSA, 1 mM DTT for 30 min at 25C in the presence of 10 M test tial lead compounds will be required. Together, thecompound. Reactions were quenched by the addition of 0.1% SDS
combination of the selectivity and the universality ofin reaction buffer plus 600 nM sensor. The initial rates of fluores-
these sensors represents a significant step forward incence signal generation at 535 nanometers were measured. Results
are reported as percentage of activity in the absence of test com- the processes of identification and development of
pound. The shaded area indicates a single standard deviation from small molecule inhibitors of protein kinases as thera-
the mean observed percent activity. Data points shown in red trian- peutics.
gles represent wells containing staurosporine.
Experimental Procedures
ADP RiboReporter sensor provide two novel formats Synthesis of Primers and Pools
Primers were synthesized either at Integrated DNA Technologieshighly suitable for universal detection of protein kinase
(IDT) or internally on an Expedite 8909 DNA synthesizer using stan-enzymatic activity. Both assay formats can be adapted
dard methods. The names and sequences of the primers used infor both low- and high-throughput applications. The de-
various experiments described below are as follows: STC.12.143.A,tection limits for kinase assays using ADP-SPA and Ri-
5-TAATACGACTCACTATAGGGCGACCCTGATGAG-3; STC.12.143.B,
boReporter sensor are approximately 50–100 nM and 5-AAAGGGCAACCTACGGCTTTCACCGTTTC-3; JD.18.25.B, 5-TAA
1–5 M ADP, respectively. While we may have hoped TACGACTCACTATAGGACGGATCGCGTGATGA-3; JD.18.25.C, 5-
TCAGGGAGGTGTGTGAGAT-3; JD.18.122.A, 5-CGAAGAAGGGAACthat the RiboReporter sensor would be more sensitive
AGAACCACGCAAGGTCAGGGAGGTGTGTGAGAT-3; JD.18.155.U, 5-than the aptamer alone, the factors that determine the
TAATACGACTCACTATAGGACCTGGCTTGGACGG-3; JD.18.155.V,sensitivity of an allosteric ribozyme are complex. Sensi-
5-AGTCCCGAGCACTTCAGGG-3; JD.37.98.B, 5-TAATACGACTtivity of the aptamer is only dependent on the affinity
CACTATAGGGACGGAGACGAGGG-3; JD.37.98.C, 5-CGAAGAA
for the ligand and the detection scheme, while sensitivity GGGAACAGAACC-3; MK.08.112A, 5-biotin-CGAAGAAGGGAAC
of the RiboReporter depends on multiple factors, includ- AGAACCACGCAA-3; MK.08.130.B, 5-TAATACGACTCACTATAG
GATGTCCAGTCGCTTGCAATGCCCTTTTAGACCCTGATGAG-3,ing the ratio of the rate constants kactive/kinactive as well as
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MK.08.66.B, 5-AGACCTACGGCTTTCACCGTTTCG-3; MK.08.87.B, fied plasmid DNA using the primers JD.18.25.B and JD.18.122A.
The primer JD.18.122A appends a sequence tag to the 3 end of5-Dabcyl-TGGGCATTGCAAGCGACTGGACATCC-3.
The DNA templates for the four pools and the minimized ADP each clone that is complementary to the biotinylated capture probe,
MK.08.112A. Clones were the transcribed as described above. Usingaptamer were prepared on an ABI Expedite 8909 DNA synthesizer
using standard methods. neutravidin-coated SPA flash plates (NEN) and prebound capture
probe (40 pmol), MK.08.112A, 5 l of individual crude clone tran-The RNA pools were prepared via run-off transcription using T7
RNA polymerase: JD18.25.A, 5-GGACGGAUCGCGUGAUGA–N40- scriptions in 25 l of PBS was captured in the plates. Unbound RNA
was removed with three washes with 200 l of PBS. Plates wereAUCUCACACACCUCCCUGA-3; JD.18.155.W, 5-AGTCCCGAGC
ACTTCAGGG AGGTGTGTGAGATGACCGTGTCTGATTGTCCGGG then patted dry on a paper towel. Treated wells were incubated with
30 l of 1 M 3H-ADP in 1 selection buffer for 30 s with shakingGTGTTCATTCCCCTCGTCATCACGCGAT CCGTCCAAGCCAGG
TCC TA TAGTGAGTCGTATTA-3. Nucleotides shown in bold were at 650 rpm and then assessed for ADP-mediated signal by quantifi-
cation on a TopCount NXT microplate and luminescence counterincorporated on the DNA synthesizer at 85% WT and 5% each of the
other three possible nucleotides. JD.37.98.A, 5-GGGACGGAGAC (Packard). The clone that gave the highest signal over background
and whose signal was least attenuated by the addition of excess ATPGAGGGGACGAAAGTCCCCGGACAATCAGACACGGTCTCCGTCC
CTTGCGTGGTTCTGTTCCCTTCTTC-3; JD.37.71.A, 5-GGGCGAC in 1 selection buffer was identified as the “best clone.” Background
was estimated based on the signal generated by surface immobiliza-CCUGAUGAGNNNNCGAGGGGGAAACCCGGACAAUCAGACACGGN
NNNCGAAACGGUGAAAGCCGUAGGUUGCCCUUU-3; JD.37.71.B, tion of unselected naive pool RNA under the same conditions. The
best clone, clone F11, was then used to estimate the lower limit of5-GGGCGACCCUGAUGAGNNNNCGGACAAUCAGACACGGUCCC
GAAAGGGACGAGNNNNCGAAACGGUGAAAGCCGUAGGUUGCCC detection of 3H-ADP in the SPA format by titrating the concentration
of 3H-ADP against both immobilized clone F11 and naive pool inUUU-3.
DNA templates containing the T7 promoter sequence (0.5 M) parallel (Figure 1B).
were incubated with 2.5 units/l T7 RNA polymerase overnight at
37C in transcription buffer (40 mM Tris [pH 7.8], 25 mM MgCl2,
1 mM spermidine, 0.1% Triton X-100, 5 mM each NTP, 40 mM DTT) Doped Reselection
JD.18.155W pool template was transcribed and purified as de-as described [73]. Reactions were quenched with 50 mM EDTA,
ethanol precipitated, and then purified on a denaturing polyacryl- scribed above. Approximately 170 pmol of purified pool RNA was
incubated in 1 reselection buffer (1% DMSO, 100 mM NaCl, 10amide gels (8 M urea, 10% acrylamide; 19:1 acrylamide:bisacrylam-
ide). Prior to use, the naive pool RNA was treated with RQ1 DNase mM MgCl2, 10 mM MnCl2, 1 mM DTT, 50 mM HEPES [pH 7.1]) plus
10 mg/ml tRNA. Pool RNA was applied to an ATP agarose pre-(Promega) under the prescribed conditions to remove residual tem-
plate DNA. column as described above with the flow through passing directly
onto the ADP agarose column. The ADP column was washed 15–20
times as described above with both reselection buffer and reselec-In Vitro Selection of an ADP-Specific Aptamer
tion buffer containing 4 mM ATP. Bound RNA was eluted with 5–8C-8-linked ADP agarose resin (Sigma) loaded at 1.6 mole/ml slurry
200 l of reselection buffer containing 4 mM ADP. Eluted RNA waswas used as the selection substrate. Two types of pre-column were
precipitated with ethanol and amplified by reverse transcription andused. In rounds 1–9, pool RNA was passed over an agarose column
PCR amplification as described above using the primers JD.18.155Uderivatized with adipic acid dihydrazide (AAD-agarose) to remove
and JD.18.155V. After three rounds of reselection, the pool wasmatrix binders. In rounds 10–16, molecules lacking the ability to
cloned and sequenced as described above. Sequences weredifferentiate between ATP and ADP were removed by passing them
aligned and analyzed for conservation and covariation using theover an agarose column derivatized with C-8-linked ATP (5 mole/l;
programs Bioedit and Clustal.Sigma).
Both the pre-column (AAD-agarose or ATP-agarose) and the sub-
strate (ADP-agarose) resins (100–400 l, depending on the round)
Measurement of Dissociation Constantswere added to disposable 1 cm columns and equilibrated with selec-
for Aptamer:Ligand Complexestion buffer (50 mM HEPES [pH 7.4], 25 mM MgCl2, 150 mM NaCl)
Preparation of Biotin-Labeled ADP Aptamercontaining 10 g/ml tRNA. The pre-column was inserted directly
The minimized aptamer was transcribed off of a PCR product madeinto the top of the ADP column to allow pool RNA to flow directly
by amplification of the JD.37.98A DNA template with the primersfrom one column to the next. Trace 32P-labeled pool RNA (round 1,
JD.37.98B and JD.87.98C. The minimized ADP aptamer was purified7 nmole; subsequent rounds, 100–500 pmole) in 200–300l selection
on denaturing PAGE and then biotinylated at the 3 end using abuffer was added to the resin and incubated for 5 min. The resin
two-step process. RNA (10M) was incubated with 10 mM sodiumwas washed between 12 and 35 times with 200–300 l of selection
metaperiodate and 75 mM sodium acetate (pH 5.4) for 1 hr on icebuffer (in rounds 6–16, washes with selection buffer containing 4
in the dark. The oxidized RNA was desalted with a Centrisep gelmM ATP were included). After the third wash, the pre-column was
filtration column (Princeton Separations), then resuspended at aremoved and the wash solutions were added directly to the ADP
concentration of approximately 4 M in a reaction mix containingcolumn. Throughout, each wash fraction was incubated on the resin
150 mM sodium acetate (pH 5.4) and 2 mM biotin thiosemicarbazide.for 2–3 min. To elute specifically bound RNA molecules, the resin
The mixture was reacted for 2 hr at room temperature with shakingwas treated with from 4–8 aliquots of selection buffer containing 4
at 500 rpm. The RNA was purified using a Centrisep gel filtrationmM ADP. All fractions were quantified using the Bioscan QC 2000
counter (Bioscan, Inc., Washington, D.C.). The elution fractions were column that had been pre-equilibrated with water. Biotinylated ap-
combined, and 25 mM EDTA, 40 g glycogen, and 1 volume of tamer (5 pmole/well) was immobilized to streptavidin flash plates
isopropanol were added to precipitate the pool RNA. The recovered (NEN) by incubation in 25 l PBS plus 0.05% tRNA, 0.025% Tween
RNA was hybridized to JD.18.25.C and reverse transcribed (Super- 20 with shaking at 650 rpm for 30 min. Unbound biotinylated aptamer
script II, Invitrogen), then amplified by PCR (Taq polymerase, In- probe was rinsed from the plate with three 1 PBS washes and
vitrogen) using the primers JD.18.25.B and JD.18.25.C according to dried.
recommended standard protocols. Pool RNA for subsequent rounds To determine the dissociation constants for ADP and its analogs,
of selection were transcribed as described in the pool preparation treated wells were incubated with 30 l of 1 M 3H-ADP in 1
section. reselection buffer for 30 s with shaking at 650 rpm and then assessed
for ADP-mediated signal by quantification on a TopCount NXT mi-
croplate and luminescence counter (Packard). Thereafter, 1 l ofClonal Analysis and Sequencing
each test compound was added to the appropriate wells, and theAfter the sixteenth round of selection, the amplified selected pool
plate was shaken at 650 rpm for 30 s prior to recounting. TitrationPCR product was cloned using the TOPO-TA cloning kit from In-
of each test compound was continued with subsequent 1 l addi-vitrogen following standard protocols. Agar plates were sent to Lark
tions up to between 1 and 10 mM final concentrations (dependingTechnologies (Houston, TX) for growth, DNA purification, and se-
quencing. Individual aptamer clones were PCR amplified from puri- on solubility and ability to compete with ADP). Affinities of various
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ligands for the aptamer were estimated from the IC50 of the competi- ADP RiboReporter Sensor-Based Assay for Kinase Activity
Preparation of Fluorescein-Labeled RiboReporter Sensortive binding curves by fitting the data to the following equation:
The template for the ADP RiboReporter sensor (SCK.46.58.A3) was
% bound 3H-ADP  % bound 3H-ADP0/(1 	 ([competitor]/IC50comp.)). amplified by PCR using the primers MK.08.130.B and MK.08.66.B
by standard protocols (Taq polymerase, Invitrogen). The template
was used to program in vitro transcription using the protocol de-
scribed above. The transcripts were desalted using a Nap5 gel filtra-ADP Aptamer-Based Assay for Kinase Activity
tion column (Pharmacia), then quantitated by OD260. Next, the RNAThe assay for pERK2 kinase activity was configured in 96-well SPA
(50 M) was incubated with 10 mM sodium metaperiodate and 300format [26]. The ADP aptamer was appended with a tag at the 3
mM sodium acetate (pH 5.4) for 1 hr on ice in the dark. Followingend to allow the aptamer to be immobilized onto the surface of an
precipitation with 200 l isopropanol, the 3-oxidized RNA was re-NEN streptavidin coated flash plate via base pairing with a biotinyl-
suspended at a concentration of approximately 40 M in a reactionated DNA capture oligo MK08.112A. Flash plates (NEN) were pre-
mix containing 250 mM sodium acetate (pH 5.4) and 3 mM fluores-pared by incubating the individual wells with 40 pmol of MK08.112A
cein thiosemicarbazide (7% DMSO final). The mixture was reactedbiotinylated capture probe in 22 l of PBS plus 0.05% tRNA, 0.025%
for 2 hr at room temperature, after which the labeled nucleic acid wasTween-20 with shaking at 650 rpm for 15 min. Excess capture probe
precipitated, purified by gel-electrophoresis on a 10% denaturingwas removed from the wells by washing with PBS three times,
polyacrylamide gel, and resuspended in H2O to a final concentrationinverting plates with force sufficient to remove liquid, and blotting
of 12 M.them dry on paper towels. Transcription reactions of the minimized
To generate the RiboReporter sensor, the fluorescein-labeledADP aptamer containing capture probe sequence (5 l, 5 pmole)
transcript was annealed to the quenching oligonucleotidein 25 l 1 PBS were incubated in designated wells with shaking
MK.08.87.B in 10 mM Tris (pH 7.4), 50 mM NaCl.at 650 rpm for 30 min. Excess aptamer was removed by washing
pERK kinase activity was measured by combining 25 nM activatedwith 1 PBS three times and blotting as described above.
pERK with 100 M ATP and 100 M ERKtide in 50 mM HEPES (pHConversion of 3H-ATP to 3H-ADP as a result of phosphorylation
8.0), 100 mM NaCl, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM DTT forof MBP (Sigma) by pERK was measured by capture of 3H-ADP onto
30 min at 25C in the presence or absence of 10 M test compoundthe plate surface. pERK was generated from ERK2 by activation with
in 50 l. Reactions were quenched by the addition of an equalconstitutively active MEK-1 mutant (MEK-DD) [74, 75] and separated
volume of 0.1% SDS in reaction buffer plus 600 nM RiboReporterfrom unphosphorylated ERK2 using a MonoQ column. Flash plates
sensor. The fluorescence signal at 535 nanometers versus time wascontaining individual reaction mixtures comprised of 40 nM pERK,
monitored on a Fusion -FP plate reader. Relative kinase activity5 M MBP, and 1.35 M 3H-ATP in 50 l buffer (1% DMSO, 100
was estimated based on the initial rate of the cleavage reaction ofmM NaCl, 10 mM MgCl2, 10 mM MnCl2, 1 mM DTT, 50 mM HEPES
the RiboReporter sensor, which is determined by the concentration[pH 7.1]) were incubated in a TopCount plate reader at room temper-
of ADP in the solution.ature. Each well was counted approximately every 5 min. Reaction
rates were estimated from the slope of the initial phase of the reac-
tions. Acknowledgments
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